YAP Subcellular Localization and Hippo Pathway Transcriptome Analysis in Pediatric Hepatocellular Carcinoma
暂无分享,去创建一个
A. Perez-Atayde | K. Vakili | Heung Bae Kim | M. Laquaglia | Khashayar Vakili | Ghazaleh Sadri-Vakili | Michael J. LaQuaglia | James L. Grijalva | Kaly A. Mueller | Antonio R. Perez-Atayde | G. Sadri-Vakili | J. Grijalva
[1] D. Calvisi,et al. Activation of β-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. , 2014, Gastroenterology.
[2] James S. Davis,et al. A review of 218 pediatric cases of hepatocellular carcinoma. , 2014, Journal of pediatric surgery.
[3] R. Yeung,et al. Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma , 2016, Pediatric blood & cancer.
[4] M. Wigler,et al. Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.
[5] Fair M. Vassoler,et al. Cocaine-Induced Chromatin Remodeling Increases Brain-Derived Neurotrophic Factor Transcription in the Rat Medial Prefrontal Cortex, Which Alters the Reinforcing Efficacy of Cocaine , 2010, The Journal of Neuroscience.
[6] G. Perilongo,et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Lanfen Chen,et al. The Hippo signaling pathway in liver regeneration and tumorigenesis. , 2015, Acta biochimica et biophysica Sinica.
[8] V. Vacic,et al. Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma , 2014, Science.
[9] Jun O. Liu,et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.
[10] E. Montgomery,et al. Expression of Yes-associated protein in common solid tumors. , 2008, Human pathology.
[11] J. Avruch,et al. Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development , 2010, British Journal of Cancer.
[12] D. Perek,et al. Liver transplantation in children with hepatocellular carcinoma Do Milan criteria apply to pediatric patients? , 2009, Pediatric transplantation.
[13] M. Esteller,et al. Unique genomic profile of fibrolamellar hepatocellular carcinoma. , 2015, Gastroenterology.
[14] G. Yochum,et al. Intersection of Hippo/YAP and Wnt/β-catenin signaling pathways. , 2013, Acta biochimica et biophysica Sinica.
[15] M. Katoh,et al. Function and cancer genomics of FAT family genes , 2012, International journal of oncology.
[16] P. Czauderna. Adult type vs. Childhood hepatocellular carcinoma--are they the same or different lesions? Biology, natural history, prognosis, and treatment. , 2002, Medical and pediatric oncology.
[17] H. Karakayalı,et al. Liver transplantation for hepatocellular carcinoma in children , 2008, Pediatric transplantation.
[18] M. Roncalli,et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. , 2014, Journal of hepatology.
[19] A. Pobbati,et al. Emerging roles of TEAD transcription factors and its coactivators in cancers , 2013, Cancer biology & therapy.
[20] H. Stein,et al. New approach to assessing lung tumours in man. , 1986, Journal of clinical pathology.
[21] A. Schmitt,et al. Opposing roles of angiomotin-like-1 and zona occludens-2 on pro-apoptotic function of YAP , 2012, Oncogene.
[22] H. Schmidt,et al. Increased brain‐derived neurotrophic factor (BDNF) expression in the ventral tegmental area during cocaine abstinence is associated with increased histone acetylation at BDNF exon I‐containing promoters , 2012, Journal of neurochemistry.
[23] F. Camargo,et al. Dynamic alterations in Hippo signaling pathway and YAP activation during liver regeneration. , 2014, American journal of physiology. Gastrointestinal and liver physiology.
[24] C. Gilles,et al. Regulation of membrane-type 1 matrix metalloproteinase expression by zonula occludens-2 in human lung cancer cells , 2013, Clinical & Experimental Metastasis.
[25] R. Jaenisch,et al. YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells , 2007, Current Biology.
[26] J. Quinn,et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] G. Feldmann,et al. Elucidation of a Universal Size-Control Mechanism in Drosophila and Mammals , 2007, Cell.
[28] G. G. Galli,et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. , 2014, Cancer cell.
[29] M. Tsao,et al. Tight junction protein zo‐2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma , 1999, International journal of cancer.
[30] V. Ng,et al. Critical review of controversial issues in the management of advanced pediatric liver tumors , 2011, Pediatric blood & cancer.
[31] E. Hiyama,et al. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy , 2014, Current opinion in pediatrics.
[32] Kevin J. Cheung,et al. Tumor Suppressor LATS1 Is a Negative Regulator of Oncogene YAP* , 2008, Journal of Biological Chemistry.
[33] Jeannie T. Lee,et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. , 2009, Cancer cell.
[34] Jianmin Zhang,et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon , 2006, Proceedings of the National Academy of Sciences.
[35] S. Vandenberg,et al. The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP. , 2008, Neoplasia.
[36] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[37] Caroline H. Diep,et al. Down-Regulation of Yes Associated Protein 1 Expression Reduces Cell Proliferation and Clonogenicity of Pancreatic Cancer Cells , 2012, PloS one.
[38] K. Ishak,et al. Comparison of tumor pathology with duration of survival of north american patients with hepatocellular carcinoma , 1995, Cancer.
[39] H. Sasaki,et al. Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling , 2008, Development.
[40] Janet Rossant,et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-β-SMAD pathway. , 2010, Developmental cell.
[41] Frank Bergmann,et al. Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. , 2013, Gastroenterology.
[42] E. López-Bayghen,et al. Zona occludens-2 inhibits cyclin D1 expression and cell proliferation and exhibits changes in localization along the cell cycle. , 2008, Molecular biology of the cell.
[43] Stefano Monti,et al. A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma , 2015, Molecular Cancer Research.
[44] Gary D Bader,et al. Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. , 2010, The Biochemical journal.
[45] U. Apte,et al. Deregulation of Hippo kinase signalling in Human hepatic malignancies , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[46] K. Guan,et al. Hippo pathway regulation of gastrointestinal tissues. , 2015, Annual review of physiology.
[47] M. Laakso,et al. Par6G suppresses cell proliferation and is targeted by loss-of-function mutations in multiple cancers , 2015, Oncogene.
[48] Bill Bynum,et al. Lancet , 2015, The Lancet.